CN113143782B - Cosmetic composition for improving epidermal aging and application thereof - Google Patents
Cosmetic composition for improving epidermal aging and application thereof Download PDFInfo
- Publication number
- CN113143782B CN113143782B CN202110479670.6A CN202110479670A CN113143782B CN 113143782 B CN113143782 B CN 113143782B CN 202110479670 A CN202110479670 A CN 202110479670A CN 113143782 B CN113143782 B CN 113143782B
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- composition
- weight
- fucose
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition for improving epidermal aging, which comprises 0.01-2.5 parts by weight of L-lactic acid.
Description
Technical Field
The invention relates to the field of daily chemical industry, in particular to an anti-aging cosmetic and a preparation method and application thereof.
Background
The skin consists of an epidermal layer, a dermal layer and subcutaneous adipose tissue. The epidermis layer is located above the dermis layer and is more directly in contact with the external environment and cosmetics. Aging of the epidermal layer has led to an increasing emphasis in the field of dermatology. Important characteristics of epidermal layer senescence include (1) deterioration in keratinocyte division ability, reduction in the thickness of the viable epidermal layer, and (2) deterioration in barrier repair function. Retinoids have the effect of improving aging of epidermal layers (e.g., thickening the viable epidermal layer) in addition to improving aging of dermal layers. More importantly, the anti-aging effect of retinoids in the first 6 months is mainly due to their improvement in the aging of the epidermis layer, which is in line with the consumer's desire to quickly ameliorate the problem. However, retinoids, while excellent in efficacy, are very unstable, degrade rapidly in formulation and are difficult to store.
Therefore, there is a strong need in the art to provide a new product for improving aging of epidermal skin.
Disclosure of Invention
The present invention is directed to a product and method for improving epidermal skin aging.
In a first aspect of the present invention, there is provided a composition for improving epidermal aging, which comprises 0.01 to 2.5 parts by weight of L-lactic acid.
In another embodiment, the composition further comprises 0.01 to 1.0 parts by weight of L-fucose or 0.1 to 5.0 parts by weight of hydrolyzed rice protein.
In another embodiment, the weight ratio of L-lactic acid to L-fucose in the composition is 1: 0.1-5.
In another embodiment, the weight ratio of L-lactic acid to hydrolyzed rice protein in the composition is 1: 0.5-10.
In another embodiment, the composition consists of L-lactic acid and L-fucose; or the composition consists of L-lactic acid and hydrolyzed rice protein.
In a second aspect of the invention, there is provided a dermatological product comprising a composition as provided herein as described above, together with a cosmetically acceptable carrier.
In another embodiment, the composition comprising L-lactic acid and L-fucose provided by the present invention as described above is contained in an amount of 0.5 to 3wt% based on the total weight of the product; or
The composition comprising L-lactic acid and hydrolyzed rice protein according to the present invention as described above is contained in an amount of 1 to 5wt% based on the total weight of the product.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In a third aspect of the invention, there is provided a method of preparing a dermatological product as described above, the method comprising the steps of: the composition provided by the present invention as described above is mixed with a cosmetically acceptable carrier to give the skin product provided by the present invention as described above.
In a fourth aspect of the invention, there is provided the use of a composition as provided by the invention as described above, as a cosmetic functional ingredient; preferably, the function comprises anti-epidermal senescence.
In a fifth aspect of the invention, there is provided a method of combating skin ageing comprising applying an effective amount of a composition as provided herein and as described above.
Accordingly, the present invention provides a novel product for improving skin aging of the epidermal layer.
Drawings
FIG. 1 shows the effect of the composition of test example 1 on promoting the expression of PCNA (Proliferating Cell Nuclear Antigen) in keratinocytes.
FIG. 2 shows the effect of the composition of test example 2 on the promotion of PCNA expression in keratinocytes.
Detailed Description
The present inventors have made extensive and intensive studies and have found that the combination of L-lactic acid with L-fucose and hydrolyzed rice protein, respectively, is effective in improving the aging status of the epidermal layer. On the basis of this, the present invention has been completed.
As used herein, "L-lactic acid" is a small molecule alpha-hydroxy acid of the L-structure. The structure is shown as the following formula I:
as used herein, "L-fucose" is a 6-deoxy-galactose. The structure is shown as the following formula II:
as used herein, "hydrolyzed rice protein" refers to a substance of rice di-and/or tri-peptides (> 4%) obtained by enzymatic digestion processes. In one embodiment of the present invention, rice oligopeptides from Silab corporation are used
As hydrolyzed rice protein.
As used herein, "epidermis" or "epidermal layer" are used interchangeably and refer to the keratinized stratified squamous epithelium, the outermost layer of the skin, differentiated from the ectoderm, through which the appendages of the skin occur. The epidermis includes keratinocytes, melanocytes, langerhans cells, and merkel cells.
In this context, the term "improving" includes promoting or assisting the metabolism of the epidermis, for example promoting and assisting the division of keratinocytes to form new keratinocytes. In one embodiment of the present invention, it refers to promoting PCNA expression in keratinocytes.
As used herein, "keratinocytes" or "keratinocytes" are used interchangeably and refer to the major constituent cells of the epidermis, accounting for over 80% of the number of epidermal cells, which produce keratin during differentiation.
Herein, "rejuvenation" refers to the process by which new keratinocytes in the epidermis divide, move up, and shed old, spent keratinocytes.
The term "effective amount" is intended for the purpose of improving epidermal senescence, which amount, after a suitable period of use, is capable of achieving the effect of promoting and assisting the division of keratinocytes to form new keratinocytes.
"composition" refers to a composition that, when applied to an individual (typically a human), is capable of penetrating the skin to induce the desired epidermal aging-improving effect.
As used herein, the term "cosmetically acceptable carrier" refers to a carrier that allows a cosmetic or personal care product to be applied, including various excipients and diluents, which are not themselves essential active ingredients, and which do not have undue toxicity after application. Suitable carriers are well known to those of ordinary skill in the art. A sufficient discussion of cosmetically acceptable excipients can be found in the cosmetic hygiene specifications 2015 edition. Such carriers may include humectants, emulsifiers, thickeners, chelating agents, emollients, and the like in the composition. Such as, but not limited to, water, 1, 2-hexanediol, p-hydroxyacetophenone, butanediol, panthenol, dipotassium glycyrrhizinate, arginine, glycerol, betaine, sodium hyaluronate, propylene glycol, glyceryl stearate/PEG-100 stearate, glyceryl stearate, xanthan gum, hydroxyethyl cellulose, carbomer, disodium EDTA, isomeric hexadecanes, isooctyl palmitate, cetostearyl alcohol, polydimethylsiloxane, citric acid or a salt thereof, behenyl alcohol, beheneth, ceteth, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl ethylhexanoate, and the like.
The term "administering" as used herein means directly applying the composition to form a substantial amount of the composition on the skin of the individual to whom it is applied.
The terms "individual" or "individual" and the like are used herein to refer to a person who can receive the compositions and/or methods for application to the skin.
As used herein, "room temperature" means 15-45 deg.C, preferably 20-35 deg.C.
The present invention provides a composition comprising 0.01 to 2.5 parts by weight of L-lactic acid, for example, 0.02 to 1.0 part by weight, 0.03 to 0.05 part by weight, 0.1 to 1.5 parts by weight, 0.3 to 0.5 part by weight, 0.05 to 2.0 parts by weight, etc.
The composition provided by the invention contains 0.01-1.0 weight part of L-fucose in addition to 0.01-2.5 weight parts of L-lactic acid, for example, the L-fucose is contained in 0.07-0.5 weight part, 0.1-0.3 weight part, 0.2-0.8 weight part, 0.05-0.14 weight part, etc.
In one embodiment of the present invention, the L-lactic acid and L-fucose are contained in a weight percentage of 0.1 to 100 wt% based on the total weight of the composition.
In one embodiment of the present invention, the L-lactic acid and L-fucose are contained in a weight percentage of 0.1 to 3.0 wt%, such as, but not limited to, 0.13 to 1.3 wt%, 0.15 to 2.5 wt%, 0.8 to 2.3 wt%, 0.7 to 2.0 wt%, and the like, based on the total weight of the composition.
The weight ratio of L-lactic acid to L-fucose in the composition provided by the invention is 1:0.1-5, such as but not limited to 1:0.3-1.6, 1:0.4-3.0, 1:0.6-1.0, 1:1.1-1.7, 1:2-4 and the like.
In one embodiment of the invention, the composition provided herein is comprised of L-lactic acid and L-fucose.
The composition of the present invention contains 0.1 to 5.0 parts by weight of hydrolyzed rice protein in addition to 0.01 to 2.5 parts by weight of L-lactic acid, for example, 0.3 to 1.0 part by weight, 0.2 to 3.0 parts by weight, 0.5 to 4.0 parts by weight, 2.0 to 3.5 parts by weight, etc.
In one embodiment of the present invention, the L-lactic acid and the hydrolyzed rice protein are contained in an amount of 0.1 to 100 wt% based on the total weight of the composition.
In one embodiment of the present invention, the L-lactic acid and the hydrolyzed rice protein are contained in a weight percentage of 0.1 to 5.0 wt%, such as, but not limited to, 0.2 to 1.5 wt%, 0.25 to 3.5 wt%, 0.23 to 1.0 wt%, etc., based on the total weight of the composition.
The weight ratio of L-lactic acid to hydrolyzed rice protein in the composition provided by the invention is 1:0.5-10, such as but not limited to 1:0.7-1.0, 1:1.3-7.0, 1:1.0-6.0, 1:2.0-8.0, and the like.
In one embodiment of the present invention, the present invention provides a composition comprising L-lactic acid and hydrolyzed rice protein.
The compositions provided by the present invention are generally obtained by mixing L-lactic acid with L-fucose or with hydrolysed rice protein.
Further, the compositions provided herein can be combined with cosmetically acceptable carriers to provide a variety of cosmetic or personal care products that can be applied to human skin, including, but not limited to, makeup creams, sun creams, facial creams, eye creams, lotions, serums, lotions, gels, and the like.
The cosmetic or personal care product provided by the invention contains 0.5-3.0 wt% of L-lactic acid and L-fucose, such as, but not limited to, 0.7-1.3 wt%, 0.8-2.0 wt% and the like, based on the total weight of the cosmetic or personal care product.
The present invention provides cosmetic or personal care products comprising 1 to 5wt% of L-lactic acid and hydrolyzed rice protein, such as, but not limited to, 1.2 to 3.5 wt%, 1.5 to 4.5 wt%, etc., based on the total weight of the product.
In some embodiments of the present invention, the cosmetic or personal care product is obtained by combining the compositions provided herein with a cosmetically acceptable carrier that can be used to form the aqueous phase. The cosmetic acceptable for forming water phaseAcceptable carriers include, but are not limited to, glycerin, butylene glycol, 1, 2-hexanediol, p-hydroxyacetophenone, propylene glycol, panthenol, dipotassium glycyrrhizinate, arginine, carbomer, EDTA 2 One or more of Na, sodium hyaluronate, xanthan gum, betaine, hydroxyethyl cellulose, citric acid or its salt, and water.
In one embodiment of the present invention, the composition provided by the present invention is mixed with water to form an aqueous phase, and then mixed with a cosmetically acceptable carrier for the oil phase and emulsified to obtain the cosmetic or personal care product. Preferably, the cosmetic or personal care product may be formed by adding preservatives, perfumes, etc. after emulsification and cooling to room temperature.
In another embodiment of the present invention, the cosmetic or personal care product is obtained by adding the composition provided by the present invention after mixing and emulsifying the cosmetically acceptable carrier of the oil phase and the cosmetically acceptable carrier of the water phase. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after emulsification and cooling to room temperature.
In another embodiment of the invention, the cosmetic or personal care product may also be obtained by adding the composition provided by the present invention after homogenization of the aqueous cosmetically acceptable carrier. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after homogenization and cooling to room temperature.
In some embodiments of the invention, the cosmetically acceptable carrier used to form the oil phase includes, but is not limited to, one or more of glyceryl stearate, glyceryl monostearate, glyceryl stearate/PEG-100 stearate complex, isomeric hexadecanes, isooctyl palmitate, ethylhexyl palmitate, cetearyl alcohol, behenyl alcohol, cetostearyl alcohol, ceteth, dimethicone, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl ethylhexanoate petrolatum, shea butter, squalane, lecithin.
Although numerical ranges and parameters setting forth the broad scope of the invention are approximate, the values set forth in the specific examples are presented as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the individual testing measurements. As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within the acceptable standard error of the mean, as considered by those skilled in the art. Except in the experimental examples, or where otherwise expressly indicated, it is to be understood that all ranges, amounts, values and percentages herein used (e.g., to describe amounts of materials, length of time, temperature, operating conditions, quantitative ratios, and the like) are to be modified by the word "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, these numerical parameters are to be understood as meaning the number of significant digits recited and the number resulting from applying ordinary carry notation.
Unless defined otherwise herein, the scientific and technical terms used herein have the same meaning as is commonly understood and used by one of ordinary skill in the art. Furthermore, as used herein, the singular tense of a noun, unless otherwise conflicting with context, encompasses the plural form of that noun; the use of plural nouns also covers the singular form of such nouns.
To make the features and effects of the present invention comprehensible to those skilled in the art, general description and definitions are made below with reference to terms and expressions mentioned in the specification and claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The theory or mechanism described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, i.e., the present disclosure may be practiced without limitation to any particular theory or mechanism.
All features defined herein as numerical ranges or percentage ranges, such as values, amounts, levels and concentrations, are for brevity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to cover and specifically disclose all possible subranges and individual numerical values (including integers and fractions) within the range.
The features mentioned above with reference to the invention, or the features mentioned with reference to the embodiments, can be combined arbitrarily. All features disclosed in this specification may be combined in any combination, provided that there is no conflict between such features and the combination, and all possible combinations are to be considered within the scope of the present specification. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
The main advantages of the invention are: the composition provided by the invention can effectively promote the keratinocyte division.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified. The weight volume percentage units in the present invention are well known to those skilled in the art and refer to, for example, the weight of solute in a 100 ml solution. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
All percentages in the examples are in wt%
Test example 1
L-lactic acid and L-fucose synergistically promote keratinocyte division renewal
Material
The test system comprises:
p4-generation keratinocytes (human primary skin cells, batch No.: EP20200519, EP20200708) were produced and supplied by Guangdong Boxi Biotech Co., Ltd.
The main reagents are as follows:
PBS (Solebao), MTT (Sigma), DMSO (Sigma), KC2500 (Guangdong Boxi organism), RNAioso Plus (TaKaRa), chloroform (national drug group), absolute ethyl alcohol (national drug group), DEPC water (Beyotime), reverse transcription kit (TaKaRa), fluorescent dye (TaKaRa).
The main equipment is as follows:
CO2 incubator (Thermo, 150i), clean bench (SW-CJ-1F, Antai Suzhou), inverted microscope (Olympus, CKX41), microplate reader (BioTek, Epoch), high-speed refrigerated centrifuge (Changshan Xiang apparatus, H1850R), general PCR apparatus (BIO-RAD, TC-XP-G), real-time fluorescence quantitative PCR apparatus (BIO-RAD, CFX96)
L-lactic acid from Corbion
L-fucose was purchased from Jennewein Biotechnologie gmbh
Method
Cell inoculation:
keratinocytes were seeded at a seeding density of 2.5E 5/well in 6-well plates and incubated overnight in an incubator (37 ℃, 5% CO2, 95% RH).
Preparing a working solution:
control group: the keratinocytes are in a normal state, i.e. a medium inoculated with cells (medium purchased from test system suppliers).
0.03 wt% L-lactic acid: l-lactic acid was dissolved in a medium for cell inoculation to dilute the L-lactic acid to a working concentration of 0.03 wt%.
0.1 wt% L-fucose: l-fucose was dissolved in a medium for cell inoculation to dilute L-fucose to a working concentration of 0.1 wt%.
Administration: when the cell plating rate in the 6-hole plate reaches 40-60%, the grouped administration is carried out, no component is used in the control group, the 0.03 wt% L-lactic acid group, the 0.1 wt% L-fucose group and the 0.03 wt% L-lactic acid and 0.1 wt% L-fucose group are all administered by 2mL of the prepared working solution in each hole, and each group is provided with 3 repeated groupsAnd (4) a hole. After completion of the administration, the 6-well plate was placed in an incubator (37 ℃ C., 5% CO) 2 95% RH) for 24 hours.
Collecting a sample: after the incubation, the cells were washed twice with 2 mL/well PBS, 1mL of RNAioso Plus was added to each well, and the lysed cells were aspirated and collected.
Gene detection: synthesizing cDNA with RNA as template according to the product instruction of RNA reverse transcription kit (TaKaRa DRR037A), performing real-time PCR reaction, placing the added reactant system in a real-time fluorescence quantitative PCR apparatus (BIO-RAD), and performing quantitative PCR reaction according to SYBR Premix Ex Taq TM II, the instruction book of the fluorescent dye product sets a reaction program, and the program is operated to detect gene expression after the information is confirmed to be correct. After the qRT-PCR data is derived, 2 is adopted according to the qRT-PCR data analysis file -△△Ct The calculation method is used for data processing, analysis and summarization. The final results are shown in the form of a chart of the qRT-PCR data summary file.
The specific calculation formula is as follows:
and (4) result statistical analysis: when the graph pad Prism Program software is used for drawing, the sample group and the control group are subjected to t-test statistical analysis, p <0.05 indicates that the difference is significant, and p <0.01 indicates that the difference is extremely significant.
Results
See figure 1.
The expression of PCNA in keratinocytes in the control group was assigned to 1. L-lactate and L-fucose had a weak enhancing effect on PCNA expression in keratinocytes, but there was no statistically significant difference. However, when the two are used in combination, the expression of PCNA increases by 305% (p <0.01), indicating that the two synergistically promote the renewal of keratinocyte division, i.e., promote keratinocyte division to promote epidermal layer renewal.
Test example 2
L-lactic acid and hydrolyzed rice protein synergistically promote keratinocyte division renewal
Material
The test system comprises:
p4-generation keratinocytes (human primary skin cells, batch No.: EP20200519, EP20200708) were produced and supplied by Guangdong Boxi Biotech Co., Ltd.
The main reagents are as follows:
PBS (Solebao), MTT (Sigma), DMSO (Sigma), KC2500 (Guangdong Boxi organism), RNAioso Plus (TaKaRa), chloroform (national drug group), absolute ethyl alcohol (national drug group), DEPC water (Beyotime), reverse transcription kit (TaKaRa), fluorescent dye (TaKaRa).
The main equipment is as follows:
CO2 incubator (Thermo, 150i), clean bench (SW-CJ-1F, Antai Suzhou), inverted microscope (Olympus, CKX41), microplate reader (BioTek, Epoch), high-speed refrigerated centrifuge (Changshan Xiang apparatus, H1850R), general PCR apparatus (BIO-RAD, TC-XP-G), real-time fluorescence quantitative PCR apparatus (BIO-RAD, CFX96)
L-lactic acid from Corbion
Hydrolyzed rice protein from Silab, a Rice oligopeptide
Method
Cell seeding
Keratinocytes were seeded at a seeding density of 2.5E 5/well in 6-well plates and incubated overnight in an incubator (37 ℃, 5% CO2, 95% RH).
Preparing a working solution:
control group: the keratinocytes are in a normal state, i.e. a medium inoculated with cells (medium purchased from test system suppliers).
0.03 wt% L-lactic acid: l-lactic acid was dissolved in a medium for cell inoculation to dilute the L-lactic acid to a working concentration of 0.03 wt%.
0.2 wt% hydrolyzed rice protein: hydrolyzed rice protein was dissolved in a medium for cell inoculation to dilute the hydrolyzed rice protein to a working concentration of 0.2 wt%.
Administration: when the cell plating rate in the 6-well plate reaches 40-60%, the grouped administration is carried out, and the control group does not use any component, namely 0.03 wt% of L-lactic acid group, 0.2 wt% of hydrolyzed rice protein group and 0.03 wt% of L-lactic acid and 0.2 wt% of hydrolyzed riceThe proteome is administrated by using 2mL of the prepared working solution in each hole, and each group is provided with 3 compound holes. After completion of the administration, the 6-well plate was placed in an incubator (37 ℃ C., 5% CO) 2 95% RH) for 24 hours.
Collecting a sample: after the incubation, the cells were washed twice with 2 mL/well PBS, 1mL of RNAioso Plus was added to each well, and the lysed cells were aspirated and collected.
Gene detection: synthesizing cDNA with RNA as template according to the product instruction of RNA reverse transcription kit (TaKaRa DRR037A), performing real-time PCR reaction, placing the added reactant system in a real-time fluorescence quantitative PCR apparatus (BIO-RAD), and performing quantitative PCR reaction according to SYBR Premix Ex Taq TM II, the instruction book of the fluorescent dye product sets a reaction program, and the program is operated to detect gene expression after the information is confirmed to be correct. After the qRT-PCR data is derived, 2 is adopted according to the qRT-PCR data analysis file -△△Ct The calculation method is used for data processing, analysis and summarization. The final results are shown in the form of a chart of the qRT-PCR data summary file.
The specific calculation formula is as follows:
and (3) statistical analysis of results: when the graph pad Prism Program software is used for drawing, the sample group and the control group are subjected to t-test statistical analysis, p <0.05 indicates that the difference is significant, and p <0.01 indicates that the difference is extremely significant.
As a result, the
See figure 2.
The expression of PCNA in keratinocytes in the control group was assigned to 1. L-lactate had a weak effect on the expression of PCNA in keratinocytes, but there was no statistically significant difference. The expression of PCNA is improved by 43.9% by hydrolyzing the rice protein; when the two are used in combination, the expression of PCNA is increased by 606% (p <0.01), which shows that the two synergistically promote the division renewal of keratinocytes, i.e. promote the keratinocyte division to promote the epidermal layer renewal.
Use example 1
Essence water
The above formulations 1-4, respectively stored at 5 deg.C, normal temperature (25 deg.C) and 45 deg.C for 3 months, all passed the stability test commonly used in the art.
Use example 2
Face cream
The above formulations 1-4, respectively stored at 5 deg.C, normal temperature (25 deg.C) and 45 deg.C for 3 months, all passed the stability test commonly used in the art.
The foregoing is merely a preferred embodiment of the invention and is not intended to limit the scope of the invention, which is defined by the claims appended hereto, and any other technical entity or method that is encompassed by the claims as broadly defined herein, or equivalent variations thereof, is contemplated as being encompassed by the claims.
Claims (6)
1. A composition for improving epidermal aging, which comprises 0.01 to 2.5 parts by weight of L-lactic acid and 0.01 to 1.0 part by weight of L-fucose, or comprises 0.01 to 2.5 parts by weight of L-lactic acid and 0.1 to 5.0 parts by weight of hydrolyzed rice protein; wherein the weight ratio of the L-lactic acid to the L-fucose is 1:0.1-5, and the weight ratio of the L-lactic acid to the hydrolyzed rice protein is 1: 0.5-10.
2. A dermatological product comprising the composition of claim 1 and a cosmetically acceptable carrier.
3. The product of claim 2, wherein the composition of L-lactic acid and L-fucose according to claim 1 is contained in an amount of 0.5 to 3wt%, based on the total weight of the product; or
The composition of claim 1 comprising L-lactic acid and hydrolyzed rice protein in an amount of 1-5wt% based on the total weight of the product.
4. A method of preparing a dermatological product according to claim 2 or 3, comprising the steps of: mixing the composition of claim 1 and a cosmetically acceptable carrier to provide a dermatological product of claim 2 or 3.
5. Use of a composition according to claim 1 as a cosmetic functional ingredient.
6. A non-therapeutic method of combating skin aging which comprises applying an effective amount of a composition according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110479670.6A CN113143782B (en) | 2021-04-30 | 2021-04-30 | Cosmetic composition for improving epidermal aging and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110479670.6A CN113143782B (en) | 2021-04-30 | 2021-04-30 | Cosmetic composition for improving epidermal aging and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113143782A CN113143782A (en) | 2021-07-23 |
| CN113143782B true CN113143782B (en) | 2022-08-02 |
Family
ID=76872941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110479670.6A Active CN113143782B (en) | 2021-04-30 | 2021-04-30 | Cosmetic composition for improving epidermal aging and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113143782B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948525A (en) * | 2014-04-23 | 2014-07-30 | 广州宝生堂化妆品有限公司 | Anti-aging active composition for epidermis |
| WO2015092036A1 (en) * | 2013-12-20 | 2015-06-25 | L'oreal | Lectin-based deodorant and/or antiperspirant cosmetic compositions |
| CN105025712A (en) * | 2013-03-08 | 2015-11-04 | 西姆莱斯股份公司 | Antimicrobial compositions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7246848B2 (en) * | 2017-10-12 | 2023-03-28 | ロレアル | Processes, compositions, methods and uses for keratin fibers |
-
2021
- 2021-04-30 CN CN202110479670.6A patent/CN113143782B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105025712A (en) * | 2013-03-08 | 2015-11-04 | 西姆莱斯股份公司 | Antimicrobial compositions |
| WO2015092036A1 (en) * | 2013-12-20 | 2015-06-25 | L'oreal | Lectin-based deodorant and/or antiperspirant cosmetic compositions |
| CN103948525A (en) * | 2014-04-23 | 2014-07-30 | 广州宝生堂化妆品有限公司 | Anti-aging active composition for epidermis |
Non-Patent Citations (4)
| Title |
|---|
| Fermentation of Seaweed Sugars by Lactobacillus Species and the;Hyeong Jin Hwang;《Biotechnology and Bioprocess Engineering》;20111231;第1231-1239页 * |
| Manufacture and characterization of pasta made with wheat flour rendered gluten-free using fungal proteases and selected sourdough lactic acid bacteria;Curiel, Jose Antonio;《JOURNAL OF CEREAL SCIENCE》;20141231;第79-87页 * |
| 大米发酵制品研究进展;高志鹏等;《农村经济与科技》;20191231;70-72页 * |
| 褐藻糖胶药理活性研究进展;张也等;《中国海洋药物》;20191231;第74-81页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113143782A (en) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1732500B1 (en) | Cosmetic composition and method for retarding hair growth | |
| US20010025056A1 (en) | Hydroxystilbenes for reducing/inhibiting protein glycation and combating skin aging | |
| WO2011059866A2 (en) | Composition and methods for improving skin appearance | |
| TWI774046B (en) | Use of solanum muricatum fermented liquid for preparing a composition for promoting skin anti-aging ability, promoting anti-glycation ability, reducing melanin content, increasing skin moisturization, reducing skin texture, reducing skin wrinkles, reducing skin redness and/or reducing fat | |
| JP5840851B2 (en) | Medicinal agent containing plum extract as active ingredient | |
| US11213472B2 (en) | VEGFC production promoter | |
| CN113509400A (en) | Skin composition and application thereof, whitening and brightening cosmetic composition and preparation method thereof | |
| JP2000212082A (en) | Preparation for external use for skin | |
| TWI784229B (en) | Lonicera japonica thunb ferment, preparation method thereof and use thereof for improving skin appearance and anti-aging | |
| CN115463048A (en) | Acne-removing face-refreshing essence and preparation method thereof | |
| EP3395324A1 (en) | Anti-aging agent and anti-aging composition for skin | |
| JP2022536333A (en) | Methods of inhibiting PAR2 activation and compositions therefor | |
| JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
| JP2006290873A (en) | Aquaporin expression promoter | |
| CN113143782B (en) | Cosmetic composition for improving epidermal aging and application thereof | |
| CN113081878B (en) | Combination for synergistically promoting synthesis of hyaluronic acid in skin and application thereof | |
| JP5366358B2 (en) | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method | |
| CN113317998A (en) | Anti-aging component for promoting collagen circulation and application thereof | |
| JP4754178B2 (en) | Promotion of melanin production by lignans | |
| TW202116344A (en) | Use of hemerocallis fulva linn. extract for manufacturing of a composition for improving skin condition | |
| US20230092216A1 (en) | Active principle comprising a particular extract of punica granatum and uses for preventing and/or treating acne | |
| CN114010563A (en) | Component with brightening and anti-aging effects and application thereof | |
| EP1080719A2 (en) | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids | |
| JP7570184B2 (en) | SVCT expression promoter | |
| KR20110101727A (en) | Composition for improving skin wrinkle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |